Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Igm biosciences, inc. crawled time : 08:00 save search
Medivir to present at the Carlsquare Equity Research Investor Day
Published: 2023-12-06 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 1.56%
H: 4.75%
C: -0.77%
day research
Medivir to present at the Redeye Life Science Day
Published: 2023-11-22 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.7%
H: 0.35%
C: -5.57%
day life
Medivir to present at the Erik Penser Bank Company Event
Published: 2023-11-21 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: -1.34%
H: 1.86%
C: -3.39%
company
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA
Published: 2023-09-07 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: -0.9%
H: 9.39%
C: 9.09%
tumor lenvima
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC
Published: 2023-09-01 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.56%
H: 3.76%
C: -3.06%
unique treatment
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima
Published: 2023-06-02 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: -5.3%
H: 12.99%
C: 11.84%
lenvima study
Medivir to present at the ABGSC Life Science Summit
Published: 2023-05-30 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.88%
H: 3.1%
C: 0.96%
life
Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination
Published: 2023-04-17 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.09%
H: 13.4%
C: 4.68%
tumor
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2022
Published: 2022-04-28 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 5.05%
H: 2.47%
C: 0.22%
report
Medivir to present at the Erik Penser Bank Health Care Day
Published: 2022-02-22 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: -1.42%
H: 3.5%
C: 0.75%
day health
MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2021
Published: 2022-02-15 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 3.23%
H: 3.18%
C: 0.12%
report
Jens Lindberg takes office as CEO of Medivir on January 24
Published: 2022-01-17 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
| Email alert
Add to watchlist
ceo
Medivir to present at the H.C. Wainwright BioConnect Virtual Conference
Published: 2022-01-10 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: -3.91%
H: 2.8%
C: 0.16%
Medivir to present at the Erik Penser Bank Life Science Day
Published: 2021-12-01 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 1.71%
H: 1.08%
C: -8.42%
life science
Medivir to present at the ProHearings shared Capital Markets Day
Published: 2021-10-11 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.01%
H: 1.54%
C: -3.64%
presentation
Medivir invites to a conference call on new clinical data and further studies with MIV-818
Published: 2021-09-16 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: -2.41%
H: 6.29%
C: 5.71%
conference
Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published
Published: 2021-09-13 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.0%
H: 2.58%
C: -1.23%
phase 1 therapy phase 1b phase 2b
Medivir to present at the Wainwright Annual Global Investment Conference
Published: 2021-09-10 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: -1.27%
conference presentation
Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818
Published: 2021-08-31 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.37%
H: 1.35%
C: -2.63%
phase 1 approval phase 2 phase 3
Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement
Published: 2021-08-16 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: -5.11%
H: 1.99%
C: -4.19%
potential
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.